|Cel-Sci's Multikine, Phase III Pushing Ahead|
|By Vinny Cassano|
|Tuesday, 28 September 2010 00:00|
After receiving news that the Multikine Phase III trial had received the go-ahead to move forward in Mississippi, Cel-Sci Corp. announced on Monday that the trial will move also forward in the Russian Federation. Cel-Sci expects to have three clinical centers in Russia.
The CVM stock is still trading with volume well above the norm, but the price run has faltered over the past couple of trading sessions.
Additional approved locations for this trial are likely to roll out through the end of the year and it's possible that interim data could start rolling in by summer of next, if the speed of effectiveness demonstrated by Multikine® in the Phase II trial is any indication of what's to come.
Multikine® is the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. CEL-SCI expects to have three clinical centers in Russia, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is a major cancer in Russia.
Multikine® could eventually turn Cel-Sci into another Dendreon, if its story unfolds in a positive fashion. With a stock trading for a handful of dimes, and a market cap of 153 million, I continue to believe that the risk of an investment in CVM is well worth the potential rewards, but it is going to take patience.
CEL-SCI’s Phase III clinical trial is an open-label, randomized, multi-center study designed to determine if Multikine administered prior to current standard of care (Surgery plus Radiotherapy or Surgery plus Concurrent Chemo radiotherapy) in subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate (Head and Neck cancer) will result in an increased overall rate of survival versus the subjects treated with standard of care only. CEL-SCI’s trial will be conducted in nine countries and is expected to be the largest clinical study of head and neck cancer ever conducted. It will also be the first trial in which immunotherapy will be administered before any other traditional means of care are attempted.
Despite what bashers say, the company has spent a great deal of energy, time and money developing the technology and getting it to this satge.
Cel-Sci is also working on various treatment platforms for its LEAPS technology, including Rheumatoid Arthritis and H1N1.
Vinny also authors the popular stock investing blog VFC's Stock House.